Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.91% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.50M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1000053 | Beta 1.69 | 52 Weeks Range 0.21 - 1.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.21 - 1.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.17% | Operating Margin (TTM) -50.85% |
Management Effectiveness
Return on Assets (TTM) -2.29% | Return on Equity (TTM) -9.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 327933 | Price to Sales(TTM) 0.49 |
Enterprise Value 327933 | Price to Sales(TTM) 0.49 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 17967700 | Shares Floating 12401820 |
Shares Outstanding 17967700 | Shares Floating 12401820 | ||
Percent Insiders 51.38 | Percent Institutions 0.99 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
BioNexus Gene Lab Corp is a hypothetical company specializing in gene-based diagnostics and therapies. Its founding year and specific milestones are not defined, but its evolution is focused on advancing personalized medicine.
Core Business Areas
- Genetic Diagnostics: Development and commercialization of diagnostic tests for identifying genetic predispositions to diseases and monitoring treatment effectiveness.
- Gene Therapy: Research and development of gene therapies targeting specific genetic mutations responsible for various diseases.
- Personalized Medicine: Providing tailored treatment plans based on an individual's genetic profile, integrating diagnostics and therapies for optimal patient outcomes.
Leadership and Structure
Details of the leadership team and organizational structure are not available as this is a hypothetical company. The structure would likely consist of a CEO, CFO, CSO, and other key executives overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- GeneSight Diagnostic Test: A hypothetical diagnostic test that analyzes a patient's genes to predict their response to various medications. Market share and revenue data are unavailable. Competitors include Myriad Genetics and Invitae.
- OncoGene Therapy: A hypothetical gene therapy targeting specific oncogenes to treat cancer. Market share and revenue data are unavailable. Competitors include Novartis and Gilead Sciences.
Market Dynamics
Industry Overview
The genetic diagnostics and gene therapy industries are experiencing rapid growth, driven by advancements in genomic sequencing and increasing demand for personalized medicine.
Positioning
BioNexus Gene Lab Corp positions itself as an innovative player in the personalized medicine space, leveraging cutting-edge technologies to improve patient outcomes. Its competitive advantage lies in its novel diagnostic and therapeutic approaches.
Total Addressable Market (TAM)
The total addressable market for gene therapy and genetic diagnostics is estimated to be in the tens of billions of dollars. BioNexus Gene Lab Corp aims to capture a significant portion of this market through its differentiated offerings.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong research and development pipeline
- Expertise in gene-based diagnostics and therapies
- Potential for high-growth in personalized medicine
Weaknesses
- High research and development costs
- Regulatory hurdles for gene therapies
- Limited commercialization experience
- Reliance on strategic partnerships
Opportunities
- Expanding market for personalized medicine
- Partnerships with pharmaceutical companies
- Acquisition of complementary technologies
- Geographic expansion into new markets
Threats
- Competition from established players
- Patent disputes and intellectual property challenges
- Adverse regulatory changes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MYGN
- ILMN
- QGEN
Competitive Landscape
BioNexus Gene Lab Corp competes with larger, more established players. Its advantages include innovative technology and a focus on personalized medicine, while its disadvantages include limited resources and commercialization experience.
Major Acquisitions
GeneDx
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded diagnostic capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical data: The company has experienced rapid revenue growth in its early years.
Future Projections: Hypothetical data: Analysts project continued revenue growth of 20-30% per year over the next five years.
Recent Initiatives: Recent initiatives include launching a new diagnostic test, expanding into new geographic markets, and forming strategic partnerships.
Summary
BioNexus Gene Lab Corp, a hypothetical company, operates in the high-growth personalized medicine sector. Its innovative technology and strategic acquisitions position it well, but it faces challenges from established competitors and regulatory hurdles. The company's strong research pipeline and growing market presence are encouraging, but its reliance on partnerships and high R&D costs require careful management. The market requires to closely monitor for economic downturn affecting healthcare spending.
Similar Companies
- MYGN
- ILMN
- TMO
- DGX
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor analysis.
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice. Information is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.